PreCyte Inc Analysis
What is PreCyte Inc?
PreCyte Inc develops the Indicator Cell Assay Platform (iCAP), a blood-based diagnostic tool using standardized cultured cells as biosensors to detect disease-specific signals. The platform leverages gene expression profiling and machine learning to identify low-abundance biomarkers in patient blood. iCAP enables early detection of lung cancer and Alzheimer's disease through pan-cancer screening and neurodegeneration-focused panels.
Location
Seattle, United States
Employees
1-10
Founded
2014
Product Features & Capabilities
- Indicator Cell Assay Platform (iCAP) for blood-based early disease detection
- Gene expression profiling with machine learning for biomarker identification
- iCAP panels for lung cancer and Alzheimer's disease screening
Use Cases
Detect early-stage lung cancer in high-risk patients using blood-based iCAP testing; Screen for Alzheimer's disease in elderly populations with clinical risk factors; Identify low-abundance biomarkers in blood samples with high sensitivity and specificity; Enable companion diagnostics for drug development in oncology and neurodegeneration; Perform high-throughput screening of patient blood samples for multiple disease indications
Other Considerations
Developing iCAP panels for lung cancer and Alzheimer's disease; Founded in 2014; HQ in Seattle, WA; Employee count 2-10; Specialties in diagnostics, neurodegeneration, cancer, precision medicine, liquid biopsy, machine learning, multivariate disease classifiers, high-throughput assays, molecular diagnostics, next-generation diagnostics, companion diagnostics, multi-cancer early detection
See something that needs updating? Suggest edits to this profile.